Precede Biosciences Announces First Scientific Data from its Liquid Biopsy Platform to be Presented as an Oral Presentation at ESMO 2023

<p>Data from more than 400 patients across 15 cancers demonstrate the significance of the Precede approach to informing therapeutic decision making and clinical diagnoses BOSTON, Oct. 15, 2023 (GLOBE NEWSWIRE) — Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class liquid biopsy platform, advances its mission with a first […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/precede-biosciences-announces-first-scientific-data-from-its-liquid-biopsy-platform-to-be-presented-as-an-oral-presentation-at-esmo-2023/">Precede Biosciences Announces First Scientific Data from its Liquid Biopsy Platform to be Presented as an Oral Presentation at ESMO 2023</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>